Diagnostic value of urinary monocyte chemoattractant protein-1 in evaluating the activity of lupus nephritis: a meta-analysis. (May 2020)

• Record Type: Journal Article
• Authors: Xia, Yuan-Rui; Li, Qing-Ru; Wang, Jun-Ping; Guo, Heng-Sheng; Bao, Yu-Qing; Mao, Yan-Mei; Wu, Jun; Pan, Hai-Feng; Ye, Dong-Qing
• Is Part Of: Lupus. Volume 29:Number 6(2020)
• Page Start: 599
• Page End: 606
• Publication Date: 2020-05
• Subjects: Systemic lupus erythematosus -- monocyte chemoattractant protein-1 -- lupus nephritis -- diagnosis -- meta-analysis; Systemic lupus erythematosus -- Periodicals; 616.772005
• DOI: 10.1177/0961203320914372
• Languages: English
• ISSNs: 0961-2033

Abstract

Objective: This study aimed to assess systematically the overall diagnostic value of urinary monocyte chemoattractant protein-1 (uMCP-1) in systemic lupus erythematosus (SLE) patients with active lupus nephritis (LN). Methods: Articles from PubMed, Web of Science, EMBASE and Cochrane Library were retrieved up to 5 November 2019. Study quality was evaluated using the Quality Assessment of Diagnostic Accuracy Studies-2 tool, and statistical analyses were performed. Results: A total of seven original studies with 521 participants were included in this meta-analysis. The summary estimates were: sensitivity 0.89 (95% confidence interval (CI) 0.86–0.93), specificity 0.63 (95% CI 0.55–0.69), positive likelihood ratio 2.16 (95% CI 1.66–2.80), negative likelihood ratio 0.15 (95% CI 0.08–0.30), diagnostic odds ratio 19.40 (95% CI 7.24–51.96) and area under the curve 0.9042. Conclusion: As a non-invasive biomarker, uMCP-1 has high diagnostic accuracy for active LN.